Art. -Nr.: HY-16591

Birinapant

(Synonyms: TL32711)

44 Cited Publications

Kundenbewertung

Based on 44 publication(s) in Google Scholar

Birinapant (TL32711), a bivalent Smac mimetic, is a potent antagonist for XIAP and cIAP1 with K_ds of 45 nM and less than 1 nM, respectively. Birinapant (TL32711) induces the autoubiquitylation and proteasomal degradation of cIAP1 and cIAP2 in intact cells, which results in formation of a RIPK1: caspase-8 complex, caspase-8 activation, and induction of tumor cell death. Birinapant (TL32711) targets TRAF2-associated cIAPs and abrogates TNF-induced NF-κB activation.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.70%
CAS. Nr.: 1260251-31-7
Formel: C₄₂H₅₆F₂N₈O₆
Molecular Weight:806.94

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Birinapant Chemical Structure

CAS. Nr.: 1260251-31-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (44)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Kd: 45 nM (XIAP), <1 nM (cIAP1)^[1]

Alle IAP Isoform-spezifische Produkte anzeigen :

Alle HIV Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
MDA-MB-231	IC₅₀	10 nM Compound: 4, TL32711	Cytotoxicity against cIAP/XIAP-dependent human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTS assay Cytotoxicity against cIAP/XIAP-dependent human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 25584393]

In Vitro

Birinapant (TL32711) (30-10000 nM; 24 hours) significantly decreases the viability of SUM190 cells in a dose-dependent manner^[1].
? Birinapant (TL32711) (30-1000 nM; 4 hours) shows a significant decrease in cIAP1 levels and enhanced PARP cleavage, and induces apoptosis^[1].
? Birinapant (TL32711) binds with high affinity to the isolated BIR3 domains of cIAP1, cIAP2, and XIAP and the single BIR domain of ML-IAP and rapidly degrades TRAF2-bound cIAP1 and cIAP2 thereby inhibiting TNF-mediated NF-κB activation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

TRAIL-resistant SUM190 IBC cells
Concentration:

30, 100, 300, 1000, 10000 nM
Incubation Time:

24 hours
Result:

Significantly decreased the viability of SUM190 cells in a dose-dependent manner.

Western Blot Analysis^[1]

Cell Line:

SUM190 cells
Concentration:

30, 300, 1000 nM
Incubation Time:

4 hours
Result:

Showed a significant decrease in cIAP1 levels and enhanced PARP cleavage.

In Vivo

Birinapant (TL32711) (30 mg/kg; i.p.; every third day (*5)) shows antitumor efficacy and are devoid of overt toxicity in preclinical models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female athymic nude mice (low-passage, patient-derived xenotransplant models of ovarian cancer, colorectal cancer, and melanoma)^[2]
Dosage:

30 mg/kg
Administration:

Intraperitoneal injection; every third day (*5)
Result:

Resulted in inhibition of tumor growth.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 1260251-31-7
Appearance Solid
Molecular Weight 806.94
Formel C₄₂H₅₆F₂N₈O₆
Color Off-white to light yellow
SMILES

FC1=CC2=C(C=C1)C(C[C@H]3N(C([C@@H](NC([C@@H](NC)C)=O)CC)=O)C[C@@H](O)C3)=C(C(N4)=C(C[C@H]5N(C([C@@H](NC([C@@H](NC)C)=O)CC)=O)C[C@@H](O)C5)C6=C4C=C(F)C=C6)N2
Synonyms

TL32711
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (44)

All Cell Proliferation/Viability AssayIn Vivo Efficacy StudyFlow CytometryWB

Sort by:

Journal Impact Factor

Cancer Cell

Interleukin-1α release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity. [Abstract]

2024 Dec 9;42(12):2015-2031.e11. PMID: 39577420
Cell

CD36-mediated endocytosis of proteolysis-targeting chimeras. [Abstract]

2025 Jun 12;188(12):3219-3237.e18. PMID: 40250420

Birinapant purchased from MedChemExpress. Usage Cited in: Cell. 2025 Jun 12;188(12):3219-3237.e18. [Abstract]

Viability of shLuc+/Vec-, shCD36+/Vec-, shCD36+/CD36- HCC1806 cells determined by MTT assays after incubation with increasing concentrations of Birinapant.
Cell

Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold. [Abstract]

2019 Jul 25;178(3):585-599.e15. PMID: 31303383

Birinapant purchased from MedChemExpress. Usage Cited in: Cell. 2019 Jul 25;178(3):585-599.e15. [Abstract]

Western blot analysis of polyclonal pools of sgCtrl or sgTRAF2-expressing SK-MEL-23 melanoma cells in the presence or absence of Birinapant, and upon coculture with MART-1 T cell for indicated amounts of time.
Cancer Res

Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer. [Abstract]

2023 Oct 2;83(19):3284-3304. PMID: 37450351

Birinapant purchased from MedChemExpress. Usage Cited in: Cancer Res. 2023 Oct 2;83(19):3284-3304. [Abstract]

Cell growth studies of MCF7 cells treated with vehicle (DMSO), fulvestrant, Birinapant (100 nmol/L), and the combination for 7 days. The number of cells were measured at days 0, 3, 5, and 7.

Birinapant purchased from MedChemExpress. Usage Cited in: Cancer Res. 2023 Oct 2;83(19):3284-3304. [Abstract]

ER+/HER2- PDX tumor growth study. Mice received Birinapant (20 mg/kg I.P., 3d/week for 5 weeks).

Birinapant purchased from MedChemExpress. Usage Cited in: Cancer Res. 2023 Oct 2;83(19):3284-3304. [Abstract]

Median fluorescence intensity (MFI) quantification of MHC-I and PD-L1 levels assessed by flow cytometry in MCF7 cells grown in HD or in the presence of E2. MCF7 cells were pretreated with vehicle, fulvestrant (10 nmol/L), Birinapant (100 nmol/L) and the combination of both drugs for 48 hours.

Birinapant purchased from MedChemExpress. Usage Cited in: Cancer Res. 2023 Oct 2;83(19):3284-3304. [Abstract]

Whole-cell lysates immunoblots of ER, NF-KB subunits, and IFNg target genes in MCF7 cells grown treated with vehicle control (DMSO), Fulvestrant (10 nmol/L), Birinapant (100 nmol/L), and the combination with and without IFNg (10 ng/mL) stimulation for 24 hours.
Nat Commun

Uncovering the rewired IAP-JAK regulatory axis as an immune-dependent vulnerability of LKB1-mutant lung cancer. [Abstract]

2025 Mar 8;16(1):2324. PMID: 40057483
Nat Commun

Chemotherapy resistance in acute myeloid leukemia is mediated by A20 suppression of spontaneous necroptosis. [Abstract]

2024 Oct 24;15(1):9189. PMID: 39448591
Nat Commun

Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma. [Abstract]

2024 Feb 20;15(1):1532. PMID: 38378697
Nat Commun

NLRP3 selectively drives IL-1β secretion by Pseudomonas aeruginosa infected neutrophils and regulates corneal disease severity. [Abstract]

2023 Sep 20;14(1):5832. PMID: 37730693
Cell Death Differ

USP13 depletion sensitizes colorectal cancer cells to necroptosis by destabilizing cIAP2 proteins. [Abstract]

2025 Oct 22. PMID: 41125793
Cell Death Differ

E3 ligase TRIM25 ubiquitinates RIP3 to inhibit TNF induced cell necrosis. [Abstract]

2021 Oct;28(10):2888-2899. PMID: 33953350
Adv Sci (Weinh)

Novel CAR-T Cells Specifically Targeting SIA-CIgG Demonstrate Effective Antitumor Efficacy in Bladder Cancer. [Abstract]

2024 Aug 23:e2400156. PMID: 39178136
Leukemia

BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML. [Abstract]

2025 Dec 19. PMID: 41419608
Cell Death Dis

Clinical stage drugs targeting inhibitor of apoptosis proteins purge episomal Hepatitis B viral genome in preclinical models. [Abstract]

2021 Jun 23;12(7):641. PMID: 34162831
Cell Death Dis

Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL). [Abstract]

2020 Feb 5;11(2):94. PMID: 32024820
Dev Cell

Single-Cell and Population-Level Analyses Using Real-Time Kinetic Labeling Couples Proliferation and Cell Death Mechanisms. [Abstract]

2019 Oct 21;51(2):277-291.e4. PMID: 31564612
EMBO J

ER stress induces caspase-2-tBID-GSDME-dependent cell death in neurons lytically infected with herpes simplex virus type 2. [Abstract]

2023 Oct 4;42(19):e113118. PMID: 37646198
Oncogene

RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models. [Abstract]

2022 Jul;41(27):3524-3538. PMID: 35676324
Cell Death Discov

RB loss sensitizes triple-negative breast cancer to apoptosis induced by cellular stress. [Abstract]

2025 Nov 24;11(1):543. PMID: 41285729
Cell Death Discov

5-Iodotubercidin sensitizes cells to RIPK1-dependent necroptosis by interfering with NFκB signaling. [Abstract]

2023 Jul 26;9(1):262. PMID: 37495567
Arch Toxicol

Species, cell proliferation state and oxygen partial pressure are major factors in the in vitro toxicity of repurposed potential ADPKD drugs in human and murine renal proximal tubule cells. [Abstract]

2026 Jun 27. PMID: 42363980
Cell Biol Toxicol

Targeting p38γ synergistically enhances sorafenib-induced cytotoxicity in hepatocellular carcinoma. [Abstract]

2025 Jan 28;41(1):35. PMID: 39871031
Mol Ther Oncolytics

The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity. [Abstract]

2022 Nov 15:27:288-304. PMID: 36458202
Int J Mol Sci

Quaternary Benzophenanthridine Alkaloids Act as Smac Mimetics and Overcome Resistance to Apoptosis. [Abstract]

2023 Oct 20;24(20):15405. PMID: 37895085
Cell Oncol (Dordr)

The X-linked inhibitor of apoptosis protein (XIAP) is involved in melanoma invasion by regulating cell migration and survival. [Abstract]

2019 Jun;42(3):319-329. PMID: 30778852
Front Microbiol

Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 Infection in vitro. [Abstract]

2018 Sep 19:9:2022. PMID: 30283406

Birinapant purchased from MedChemExpress. Usage Cited in: Front Microbiol. 2018 Sep 19:9:2022. [Abstract]

ACH-2 cells are exposed to Birinapant (50 nM) in the presence or absence of PEP005 (5 nM), with TNF-α (10 ng/ml) co-treatment for 24 h, and cell lysates are used for WB analysis.
Cancers (Basel)

Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening. [Abstract]

2022 Mar 19;14(6):1575. PMID: 35326726
Exp Neurol

PGAM5 promotes RIPK1-PANoptosome activity by phosphorylating and activating RIPK1 to mediate PANoptosis after subarachnoid hemorrhage in rats. [Abstract]

2024 Nov 25:115072. PMID: 39603487
J Cell Mol Med

cIAP1/2 are involved in the radiosensitizing effect of birinapant on NSCLC cell line in vitro. [Abstract]

2021 May 3;25(13):6125-6136. PMID: 33939305
Aquaculture

2021, 736595.
Mol Med Rep

SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway. [Abstract]

2020 Mar;21(3):1251-1257. PMID: 31922244
Icahn School of Medicine at Mount Sinai

2026.
bioRxiv

2025 Oct 23.
bioRxiv

Potentiating CAR-T bystander killing by enhanced Fas/FasL signaling mitigates antigen escape in heterogeneous tumors. [Abstract]

2025 Sep 24:2025.09.22.677496. PMID: 41040218
Patent

US20250127813A1.
Hong Kong Polytechnic University

2025.
University of North Carolina at Chapel Hill

2024.
bioRxiv

SMAC mimetics induce human macrophages to phagocytose live cancer cells. [Abstract]

2024 Nov 28:2024.11.25.625306. PMID: 39651304
University of Cologne

2024.
University of Gothenburg

2023 Jun 27.
bioRxiv

2023 Mar 6.
University of Portland

2022.
Patent

US20210269505A1.
bioRxiv

2019 Nov.
University Regensburg

2017 Jul.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 125 mg/mL (154.91 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2392 mL

6.1962 mL

12.3925 mL

5 mM

0.2478 mL

1.2392 mL

2.4785 mL

10 mM

0.1239 mL

0.6196 mL

1.2392 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (2.58 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (2.58 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (2.58 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Allensworth JL, et al. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism. Breast Cancer Res Treat. 2013 Jan;137(2):359-71. [Content Brief]

[2]. Krepler C, et al. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clin Cancer Res. 2013 Apr 1;19(7):1784-94. [Content Brief]

[3]. Nguyen QD, et al. Temporal and spatial evolution of therapy-induced tumor apoptosis detected by caspase-3-selective molecular imaging. Clin Cancer Res. 2013 Jul 15;19(14):3914-24. [Content Brief]

[4]. Benetatos CA, et al. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models. Mol Cancer Ther. 2014 Apr;13(4):867-79. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.2392 mL	6.1962 mL	12.3925 mL	30.9812 mL
	5 mM	0.2478 mL	1.2392 mL	2.4785 mL	6.1962 mL
	10 mM	0.1239 mL	0.6196 mL	1.2392 mL	3.0981 mL
	15 mM	0.0826 mL	0.4131 mL	0.8262 mL	2.0654 mL
	20 mM	0.0620 mL	0.3098 mL	0.6196 mL	1.5491 mL
	25 mM	0.0496 mL	0.2478 mL	0.4957 mL	1.2392 mL
	30 mM	0.0413 mL	0.2065 mL	0.4131 mL	1.0327 mL
	40 mM	0.0310 mL	0.1549 mL	0.3098 mL	0.7745 mL
	50 mM	0.0248 mL	0.1239 mL	0.2478 mL	0.6196 mL
	60 mM	0.0207 mL	0.1033 mL	0.2065 mL	0.5164 mL
	80 mM	0.0155 mL	0.0775 mL	0.1549 mL	0.3873 mL
	100 mM	0.0124 mL	0.0620 mL	0.1239 mL	0.3098 mL

Keywords

Birinapant

44 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Birinapant

Anti-Infection Compound Library

Apoptosis Compound Library

NF-κB Signaling Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Antiviral Compound Library

Peptidomimetic Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

Protein-protein Interaction Inhibitor Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Cell Death Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Birinapant

Alle IAP Isoform-spezifische Produkte anzeigen

Alle HIV Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (44)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Birinapant

Anti-Infection Compound Library

Apoptosis Compound Library

NF-κB Signaling Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Antiviral Compound Library

Peptidomimetic Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

Protein-protein Interaction Inhibitor Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Cell Death Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Birinapant

Alle IAP Isoform-spezifische Produkte anzeigen

Alle HIV Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (44)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Birinapant Related Classifications

HY-16591 Related Classifications